Effects of UCH‐L1 on α‐synuclein over‐expression mouse model of Parkinson’s disease
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The rare inherited form of Parkinson’s disease (PD), PARK5, is caused by a missense mutation in ubiquitin carboxy‐terminal hydrolase‐L1 (UCH‐L1) gene, resulting in Ile93Met substitution in its gene product (UCH‐L1 Ile93Met). PARK5 is inherited in an autosomal‐dominant mode, but whether the Ile93Met mutation gives rise to a gain‐of‐toxic‐function or loss‐of‐function of UCH‐L1 protein remains controversial. Here, we investigated the selective vulnerabilities of dopaminergic (DA) neurons in UCH‐L1‐transgenic (Tg) and spontaneous UCH‐L1‐null gracile axonal dystrophy mice to an important PD‐causing insult, abnormal accumulation of α‐synuclein (αSyn). Immunohistochemistry of midbrain sections of a patient with sporadic PD showed αSyn‐ and UCH‐L1‐double‐positive Lewy bodies in nigral DA neurons, suggesting physical and/or functional interaction between the two proteins in human PD brain. Recombinant adeno‐associated viral vector‐mediated over‐expression of αSyn for 4 weeks significantly enhanced the loss of nigral DA cell bodies in UCH‐L1 Ile93Met‐Tg mice, but had weak effects in age‐matched UCH‐L1 wild‐type‐Tg mice and non‐Tg littermates. In contrast, the extent of αSyn‐induced DA cell loss in gracile axonal dystrophy mice was not significantly different from wild‐type littermates at 13‐weeks post‐injection. Our results support the hypothesis that PARK5 is caused by a gain‐of‐toxic‐function of UCH‐L1 Ile93Met mutant, and suggest that regulation of UCH‐L1 in nigral DA cells could be a future target for treatment of PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ramirez, A., Heimbach, A., Gründemann, J., Stiller, B., Hampshire, D., Cid, L. P., Goebel, I., Mubaidin, A. F., Wriekat, A.-L., Roeper, J., et al. (2006) · Nature Genetics · doi:10.1038/ng1884 · Cited by 1,208
Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct
Conway, K. A., Rochet, J.-C., Bieganski, R. M., & Lansbury, P. T. (2001) · Science · doi:10.1126/science.1063522 · Cited by 1,127
Choi, J., Levey, A. I., Weintraub, S. T., Rees, H. D., Gearing, M., Chin, L.-S., & Li, L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m314124200 · Cited by 568 · cited 2×
“UCH-L1 is also reported to undergo oxidative modification in the brains of patients with PD and Alzheimer’s disease (Choi et al. 2004).”
BackgroundMandir, A. S., Przedborski, S., Jackson-Lewis, V., Wang, Z.-Q., Simbulan-Rosenthal, C. M., Smulson, M. E., Hoffman, B. E., Guastella, D. B., Dawson, V. L., & Dawson, T. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5774 · Cited by 382
Norris, E. H., Giasson, B. I., Hodara, R., Xu, S., Trojanowski, J. Q., Ischiropoulos, H., & Lee, V. M.-Y. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412621200 · Cited by 273
Kabuta, T., Furuta, A., Aoki, S., Furuta, K., & Wada, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801918200 · Cited by 227 · cited 2×
“Furthermore, we reported recently that carbonyl-modified UCH-L1 shares aberrant molecular properties with UCH-L1Ile93Met, including similar secondary structural changes, increased insolubility, and elevated interaction with various proteins such as tubulin (Kabuta et al. 2008b).”
BackgroundSelf-citationα-Synuclein Overexpression Increases Cytosolic Catecholamine Concentration
Mosharov, E. V., Staal, R. G. W., Bové, J., Prou, D., Hananiya, A., Markov, D., Poulsen, N., Larsen, K. E., Moore, C. M. H., Troyer, M. D., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0519-06.2006 · Cited by 165
Cited by
Parkinson's disease: Mechanisms, translational models and management strategies
Raza, C., Anjum, R., & Shakeel, N. U. A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.03.057 · Cited by 603
Oliveras-Salvá, M., Van der Perren, A., Casadei, N., Stroobants, S., Nuber, S., D’Hooge, R., Van den Haute, C., & Baekelandt, V. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-44 · Cited by 191
“Intriguingly, the few studies with α-synuclein rAAV vectors performed in mice until now report either no or very limited dopaminergic neuron loss, with a maximum of 20 to 35% at 2 to 6 months after injection [33-38].”
BackgroundResultCorsetti, V., Florenzano, F., Atlante, A., Bobba, A., Ciotti, M. T., Natale, F., Della Valle, F., Borreca, A., Manca, A., Meli, G., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv059 · Cited by 129
Miller, S. J., Darji, R. Y., Walaieh, S., Lewis, J. A., & Logan, R. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1271941 · Cited by 16
Metadata
- Authors
- Yasuda, T., Nihira, T., Ren, Y., Cao, X., Wada, K., Setsuie, R., Kabuta, T., Wada, K., Hattori, N., Mizuno, Y., & Mochizuki, H.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2009-01-19
- Volume
- 108
- Issue
- 4
- Pages
- 932-944
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2036331449
- Cited by
- 66
- References
- 7
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of UCH‐L1 on α‐synuclein over‐expression mouse model of Parkinson’s disease. https://app.cochat.ai/papers/10.1111/j.1471-4159.2008.05827.x
- The paper
- Yasuda, T., Nihira, T., Ren, Y., Cao, X., Wada, K., Setsuie, R., Kabuta, T., Wada, K., Hattori, N., Mizuno, Y., & Mochizuki, H. (2009). Effects of UCH‐L1 on α‐synuclein over‐expression mouse model of Parkinson’s disease. Journal of Neurochemistry. https://doi.org/10.1111/j.1471-4159.2008.05827.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.